NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross...
In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
